AGX 051
Alternative Names: AGX-051Latest Information Update: 08 Feb 2023
At a glance
- Originator AgonOx; Providence Cancer Center
- Developer AgonOx
- Class Antibodies; Antineoplastics; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action OX40 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Suspended Cancer
Most Recent Events
- 06 Feb 2022 Suspended - Phase-II for Cancer in USA (Parenteral) (AgonOx pipeline, February 2023)
- 03 Jan 2022 Phase-II clinical trials in Cancer in USA (Parenteral) (AgonOx pipeline, January 2022)